The SGLT-1&2 inhibitor sotagliflozin ameliorated LA remodeling in metabolic HFpEF. It also improved distinct features of Ca 2+ -mediated cellular arrhythmogenesis in-vitro (i.e. magnitude of SCaEs, mitochondrial Ca 2+ buffer capacity, diastolic Ca 2+ accumulation, NCX activity). The safety...
LX-4211是SGLT1/2抑制剂,是抗糖尿病剂。注:本品仅可用于科研实验,严禁用于临床医疗及其他用途!CAS号:1018899-04-1别名:Sotagliflozin;LP-802034纯度:99.89%分子式:C21H25ClO5S分子量:424.94结构式:储存条件:-20℃,有效期2年,溶入溶剂后-20℃请尽量在一个月内使用。相关搜索:SGLT1/2抑制剂(LX-4211),Sota...
The IC50 values of a SGLT inhibitor phlorizin for hSGLT1 obtained using 1-NBDG and C-14-AMG were identical (0.11 mu M) in our cell-based system. The IC50 values of dapagliflozin, a well-known selective SGLT2 inhibitor, for hSGLT2 and hSGLT1 determined using 1-NBDG were 1.86 nM and...
This finding was supported by a meta-analysis of data extracted from 3 RCTs with 2 sotagliflozin (dual SGLT1/2 inhibitor) and 1 Empagliflozin suggesting net protection by the SGLT2i against cardiovascular outcomes and deaths in patients with T2D and AF [19]. Considering AF separately, a ...
Onder meer werden de resultaten bekendgemaakt van onderzoek met duale therapie met SGLT1/2-inhibitor sotagliflozin. Een tablet van 400 mg sotagliflozin eenmaal daags blijkt de glykemische controle te verbeteren bij type 1-diabetespatiënten als aanvulling op intensieve insulinetherapie. This ...
24-week efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes (inTandem2) Sawhney,S.,Banks,... - Diabetologia: Clinical and Experimental Diabetes and Metabolism = Organ of the European Association for the Study of Diabetes...
[9] LiCG, ZhangJ, XueM, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart[J]. Cardiovasc Diabetol, 2019, 18(1):15. [10] LeeTM, ChangNC, LinSZ. Dap...
Glucosuric, renal and hemodynamic effects of a dual inhibitor of SGLT1 and SGLT2, licogliflozin, in patients with chronic kidney disease: a randomized trial Background: The beneficial effects of SGLT2 inhibitors in patients with chronic kidney disease (CKD) have been demonstrated. Whether inhibit...
SGLT2 inhibitors might facilitate ATP and haemoglobin production by increasing the pool of bioreactive cytosolic Fe2+ as a result of the SGLT2 inhibitor-induced decrease in hepcidin and ferritin levels, thereby alleviating the state of inflammation-mediated functional iron deficiency that is observed in...
This review focuses on the benefits of SGLT2i for cardiomyopathy in diabetes, including the mechanism (Table 1). Future prospects are also discussed. Table 1 Therapeutic targets of SGLT2i in basic science trials Full size table SGLT2i and improved heart function The first SGLT inhibitor was ...